Anzeige
❌
Mehr »
Donnerstag, 15.10.2026 - Börsentäglich über 12.000 News
500.000 USD Mindestabnahme! Small-Cap-Aktie noch unter dem Radar
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
MC

WKN: A0YDR2 | ISIN: US5845071076 | Ticker-Symbol: N/A
1-Jahres-Chart
MEDICAL CARE TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
MEDICAL CARE TECHNOLOGIES INC 5-Tage-Chart
ACCESS Newswire
94 Leser
Artikel bewerten:
(0)

Medical Care Technologies Inc. Outlines Path to Scale AI-Powered Software Revenue After $250,000 First Agreement

Company Points to Four Active Tracks - Software Monetization, StrainScan Pro Outreach, Subsidiary Collectibles Flow, and Health Imaging R&D - as the Framework for Broader Commercial Growth

MESA, AZ / ACCESS Newswire / October 15, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today described the operating framework it is using to build on the first paid software agreement announced October 14.

That agreement is valued at up to $250,000, and the first payment has been initiated. It is the Company's first external enterprise level software revenue outside of its subsidiaries. Management views the agreement as evidence that the platform work funded by prior capital raises can now convert into commercial software income, and is organizing the rest of the business around the same objective: moving from development into paid use.

Four tracks are currently open:

Software commercialization
The October 14 agreement establishes the first external software revenue line. Execution under that agreement is underway. The Company is also evaluating additional software opportunities that fit the same deployment model. No additional agreements are being announced in this release.

StrainScan Pro
Enterprise demonstrations continue across agriculture, food distribution, and restaurant service. The platform is being shown as a configurable visual inspection layer for operators in markets the Company has previously described as multi-trillion and multi-hundred-billion dollar in scale. Feedback from those sessions is being used to refine workflows as the Company works toward first enterprise clients.

Infinite Auctions and Real Game Used
The subsidiaries completed an initial six-figure game-worn memorabilia sale to Topps, with Real Game Used providing photo-match authentication. Discussions continue on additional supply, including historic New York Knicks material following the franchise's 2026 championship. Those discussions are ongoing and have not closed.

Melanoma Scan Beta and Wound Monitoring
Both applications remain in active development. Melanoma Scan Beta continues to accept human-submitted images, with a new round of internal evaluation results expected on the corporate website in the near term. Wound Monitoring remains in internal technical evaluation following the results posted October 12. Neither application has regulatory clearance.

"The first software payment shows the build can produce revenue," said Marshall Perkins, CEO of Medical Care Technologies. "We now have a paid software agreement in motion, enterprise demonstrations running, subsidiary transactions with a major collectibles partner, and health imaging platforms advancing through testing. The objective is to grow revenue across those tracks. That is an objective, not a projection, and it is the direction the Company is executing toward."

The Company is not providing revenue guidance or share-price commentary. Progress on each track will be reported as it occurs.

About Medical Care Technologies Inc.
Medical Care Technologies Inc. (OTCID:MDCE) is a diversified technology company focused on the development and commercialization of artificial intelligence-powered applications spanning health, wellness, nutrition, lifestyle, and enterprise imaging analysis solutions. Visit: https://www.medicalcaretechnologies.com

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding commercialization priorities, ongoing demonstrations, negotiations, and development timelines. Forward-looking statements are based on current expectations and assumptions, and actual results may differ materially due to various risks and uncertainties. The company undertakes no obligation to update these statements except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements.

Contact Information:
Medical Care Technologies Inc.
1910 S. Stapley Drive, Suite 221, Mesa, AZ 85204
Phone: +1 (480) 645-0750
Email: marshall@medicalcaretechnologies.com
Website: https://www.medicalcaretechnologies.com

SOURCE: Medical Care Technologies Inc.



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/medical-care-technologies-inc.-otcid-mdce-outlines-path-to-scale-ai-p-1237103

© 2026 ACCESS Newswire
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.